Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Zelboraf (vemurafenib)
i
Other names:
RG7204, RO5185426, PLX4032, PLX-4032, R-7204, RG-7204, RO-5185426, PLX 4032, R 7204, R7204, RG 7204, RO 5185426
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(212)
News
Trials
Company:
Daiichi Sankyo, Roche
Drug class:
BRAF inhibitor, BRAF V600E inhibitor
Related drugs:
‹
dabrafenib (211)
PLX4720 (65)
avutometinib (27)
FORE-8394 (20)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
RX208 (0)
PF-07799933 (0)
encorafenib (63)
ABM-1310 (5)
CB-006-3 (1)
dabrafenib (211)
PLX4720 (65)
avutometinib (27)
FORE-8394 (20)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
RX208 (0)
PF-07799933 (0)
encorafenib (63)
ABM-1310 (5)
CB-006-3 (1)
›
Associations
(212)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600E
Ganglioglioma
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
vemurafenib
Sensitive: A2 - Guideline
vemurafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
atezolizumab + vemurafenib + cobimetinib
Sensitive: A2 - Guideline
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
vemurafenib + rituximab
Sensitive: A2 - Guideline
vemurafenib + rituximab
Sensitive
:
A2
vemurafenib + rituximab
Sensitive: A2 - Guideline
vemurafenib + rituximab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.